N-of-One Selected by Life Technologies to Provide Valuable Employee Benefit: Molecular Diagnostics and Treatment Strategies for Personalized Cancer Care
By a News Reporter-Staff News Editor at Clinical Trials Week -- N-of-One, Inc., a leading provider of molecular interpretation and therapeutic strategies for personalized cancer care, announced that global life sciences company Life Technologies (NASDAQ: LIFE) has selected N-of-One to provide a new type of benefit to its approximately 10,000 employees. For the first time, Life Technologies employees will have confidential access to personalized cancer treatment strategies as an employee benefit, including review of the most advanced treatment options available. N-of-One develops comprehensive molecular diagnostic strategies for physicians and their patients, and based on the findings of the testing, prepares comprehensive treatment reports outlining the therapeutic options available to the patients and their oncologists. The financial terms of the agreement are not disclosed (see also N-of-One, Inc.).
Dr. Paul R. Billings, Chief Medical Officer of Life Technologies, said: "Life Technologies is committed to offering the best solutions in personalized medicine. We are proud to make this new and valuable service available to our employees with cancer around the world. N-of-One is the clinical interpretation leader in personalized cancer care and a natural choice as a partner, having delivered thousands of personalized treatment and diagnostic strategy roadmaps to cancer patients and oncologists."
"We applaud Life Technologies for taking this important and innovative step to give employees access to the most current personalized cancer medicine diagnostic and treatment options available through this innovative benefit offering," said Christine Cournoyer, Chief Executive Officer of N-of-One. "N-of-One has provided interpretation of patients' molecular profiling for personalized cancer care diagnostic and treatment strategies through three channels: directly to physicians and patients, through agreements with hospitals and provider networks, and through partnerships to provide interpretation services for leading diagnostic companies."
Under the terms of the agreement, Life Technologies employees can apply confidentially to work directly with N-of-One. The N-of-One team will coordinate genomic profiling of the cancer, interpretation of the diagnostic results, and development of a comprehensive Treatment Strategy RoadmapTM within a few weeks - all at no cost to the employee. This personalized interpretation and synthesis includes the latest knowledge on cancer treatment options, both approved and in clinical trials, all specifically targeted to each patient's genetic tumor profile.
"Life Technologies plays a leading role in the evolution of personalized medicine being made possible by genetic sequencing and other advancements," said Pete Leddy, head of Global Human Resources for Life Technologies. "IMPACT gives our employees access to the same cutting-edge discoveries we are helping create in partnership with pharmaceutical and other IVD companies, and shows we're willing to walk the walk when it comes to living our values and aligning to our purpose of shaping discovery and improving life."
"N-of-One supports the physician with the latest knowledge regarding possible treatment options for the patient's specific cancer diagnosis," said Jennifer Levin Carter MD, MPH, founder and Chief Medical Officer of N-of-One. "Having these insights can make a difference; in almost 40% of the cases where N-of-One provided personalized treatment and diagnostic strategy roadmaps, the physician chose to make an immediate change to the cancer patient's treatment strategy.
Keywords for this news article include: Cancer, Genetics, Oncology, Treatment, Technology, Therapeutics, N-of-One Inc., Personalized Medicine, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC